Edition:
United Kingdom

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

29.42USD
25 Apr 2018
Change (% chg)

$0.27 (+0.93%)
Prev Close
$29.15
Open
$29.22
Day's High
$29.74
Day's Low
$28.92
Volume
66,821
Avg. Vol
107,818
52-wk High
$34.62
52-wk Low
$18.67

Chart for

About

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials... (more)

Overall

Beta: 2.15
Market Cap(Mil.): $1,163.30
Shares Outstanding(Mil.): 46.93
Dividend: --
Yield (%): --

Financials

  XNCR.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.87 -- --
ROI: -14.67 1.58 14.38
ROE: -15.16 2.41 16.07

BRIEF-Xencor Says Public Offering Of 7.30 Mln Common Shares Priced At $31 Per Share

* XENCOR ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

20 Mar 2018

BRIEF-Xencor Files For Potential Mixed Shelf Offering

* XENCOR INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING ‍​ Source text: (http://bit.ly/2G8MdV1) Further company coverage:

19 Mar 2018

BRIEF-Xencor Announces Proposed Public Offering Of Common Stock

* XENCOR, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

19 Mar 2018

BRIEF-Xencor Reports Q4 Loss Per Share $0.25

* XENCOR REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

27 Feb 2018

BRIEF-Xencor Doses First Patient In Phase 1 Study Of Xmab®18087,An Antibody For Treatment Of Neuroendocrine Tumors And Gastrointestinal Stromal Tumors

* XENCOR DOSES FIRST PATIENT IN PHASE 1 STUDY OF XMAB®18087 BISPECIFIC TUMOR TARGETING ANTIBODY FOR THE TREATMENT OF NEUROENDOCRINE TUMORS AND GASTROINTESTINAL STROMAL TUMORS

22 Feb 2018

BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus

* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS

05 Jan 2018

BRIEF-Xencor Receives Milestone Payment From Amgen

* SAYS IT HAS EARNED A $10 MILLION MILESTONE PAYMENT FROM AMGEN

05 Dec 2017

BRIEF-Xencor posts Q3 loss of $0.33 per share

* Xencor reports third quarter 2017 financial results and provides clinical pipeline update

07 Nov 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.68 -0.38
Novartis AG (NOVN.S) CHF75.24 -0.52
Roche Holding Ltd. (ROG.S) CHF217.75 -1.45
Roche Holding Ltd. (RO.S) CHF222.60 -1.20
AstraZeneca plc (AZN.L) 4,991.00 +1.50
GlaxoSmithKline plc (GSK.L) 1,412.20 -50.00
AbbVie Inc (ABBV.N) $91.87 +0.51
Bristol-Myers Squibb Co (BMY.N) $51.76 +0.18
Bristol-Myers Squibb Co (BMYMP.PK) $1,306.55 --
Amgen, Inc. (AMGN.OQ) $174.83 +2.89

Earnings vs. Estimates